stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Free cash flow
Jazz Pharmaceuticals PLC's free cash flow for fiscal 2025 was $316.1M, down 76.5% from $1.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $664.5M. Over the past ten years it has ranged from $316.1M (fiscal 2025) to $1.3B (fiscal 2024) — the current reading is the lowest in ten years. Jazz Pharmaceuticals PLC ranks 10th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $316.1M | (76.55%) |
| FY2024 | $1.3B | 28.48% |
| FY2023 | $1.0B | 35.57% |
| FY2022 | $773.8M | 5.57% |
| FY2021 | $733.0M | 40.85% |
| FY2020 | $520.4M | (14.45%) |
| FY2019 | $608.3M | (14.97%) |
| FY2018 | $715.3M | 23.52% |
| FY2017 | $579.1M | 41.61% |
| FY2016 | $409.0M | (17.55%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $493.1M | 53.81% |
| Jun 2026 | $320.6M | (17.48%) |
| Mar 2026 | $388.5M | — |
| Dec 2025 | −$537.7M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| JAZZ Jazz Pharmaceuticals PLC | $664.5M |
| BMRN BioMarin Pharmaceutical Inc. compare | $557.9M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| TECH Bio-Techne Corp compare | $263.2M |
| KYMR Kymera Therapeutics, Inc. compare | −$288.9M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.8M |
| SMMT Summit Therapeutics PLC compare | −$459.8M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement